Strategic Acquisition Opportunity Potential buyer interest from Alcon following multiple 2025 reports that Alcon plans to acquire LumiThera and its PBM device for dry AMD treatment, signaling a direct exit or partnership opportunity for sales teams to engage during the M&A process or pursue ongoing distribution in regions where Alcon may delegate product access.

Regulatory & Reimbursement Momentum Valeda has FDA authorization and a forthcoming CPT Category III code, with 2024 expansion of regulatory acceptance and a 2025 CPT code effective date, presenting a favorable backdrop for pursuing payor conversations, clinician education, and bundled service offerings to accelerate adoption.

Clinical Validation Pathways Recent topline data and ongoing clinical registries in North America and Europe create talking points for clinical partnerships, key opinion leader engagement, and sponsored studies to strengthen market credibility and expand reimbursement discussions.

Multi-Product Portfolio A diversified ophthalmic portfolio including Valeda PBM, AdaptDx Pro AI-assisted dark adaptometer, and NOVA Vision Testing System enables cross-sell and bundled solutions to ophthalmology centers, enhancing patient pathways from screening to treatment.

Global Expansion Readiness Existing EU CE Mark and select Latin American availability, combined with US and Canada access, indicate readiness for channel development, distributor partnerships, and regional market-entry plans, even as corporate activity in 2025 shapes potential collaboration dynamics.